34 results about "Analogues/Derivatives" patented technology

A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The method and system may be used for chemoprevention and/or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and/or organs. The analog, derivative, or intermediate may be administered to a cell, a group of cells, a tissue, an organ or a subject, such that at least a portion of the undesirable consequences of the proliferative disorder are thereby reduced.

This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent, for example raloxifene, or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, ester, or N-oxide, or mixtures thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibits prostate carcinogenesis and treats prostate cancer.

The present invention provides methods for reducing the incidence of, inhibiting, suppressing, reducing the incidence of, and treating androgen-deprivation induced osteoporosis, bone fractures and/or loss of bone mineral density (BMD) in men having prostate cancer, comprising administering to a male human subject having prostate cancer a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The present invention also provides methods of treating, preventing, suppressing, inhibiting, or reducing the incidence of hot flashes, gynecomastia, and/or hair loss in male humans having prostate cancer, comprising same.

A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or ulcerative colitis) or systemic causes of inflammation (e.g., endotoxemia, sepsis, hemorrhagic shock/resuscitation or pancreatitis) is disclosed. In the method of the invention, an affected patient is administered a therapeutically effective amount of a composition including an NAD-related compound, in a form that is accessible to a receptor molecule, conveyed in a pharmaceutically acceptable carrier vehicle. NAD-related compounds include nicotinamide adenine dinucleotide (NAD⁺), cyclic adenosine diphosphate ribose (cADPR), or functionally equivalent analogues, derivatives, metabolites or agonists thereof or prodrugs therefor. Also disclosed are ex vivo and in vivo assay methods to test candidate compounds for activity, kits for carrying out the therapeutic methods or the assay methods of the invention and articles of manufacture that include compositions for use in the methods of the invention and instructions for the use thereof.

The present invention relates to trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-N',N'-dimethylurea (cariprazine), its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations for use in the treatment of symptoms of autism spectrum disorder in general, and preferably the object of the present invention is to treat one or more symptoms of autism. Furthermore, it was also found that cariprazine, its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations are suitable for treatment of conditions such as Asperger's syndrome, atypical autism (otherwise known as pervasive developmental disorder not otherwise specified; PDD-NOS), Rett syndrome, childhood disintegrative disorder, attention deficit hyperactivity disorder (ADHD) and sensory integration dysfunction.

The invention relates to a fusion protein for treating diabetes and/or obesity. The structure of the fusion protein is GLP-1 or an analogue and a derivative thereof-connecting peptide-albumin binding protein, the albumin binding protein comprises an ABD structural domain (GA3, ABD035, ABDon) or a DARPin capable of targeting HSA (human serum albumin). The bottleneck problem that the half-life period of GLP-1 or Ex is short is solved by connecting the GLP-1 or Ex with an ABD structural domain or DARPin protein, so that the GLP-1 or Ex can be better applied clinically. According to the present invention, the test results show that the albumin binding protein significantly prolongs the half-life period of GLP-1 or Ex, and improves the hypoglycemic activity in mice. The modified GLP-1 or Ex has a certain body weight reducing effect and can be used for treating or assisting in treating obesity.

This invention relates to the prevention and treatment of breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of a) treating a subject suffering from breast cancer; b) preventing, suppressing, inhibiting or reducing the incidence of breast cancer in a subject; c) delaying the progression of breast cancer in a subject suffering from breast cancer; d) preventing the recurrence of breast cancer in a subject; e) treating the recurrence of breast cancer in a subject suffering from breast cancer; and/or f) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer, by administering to the subject a therapeutically effective amount of an Androgen Receptor Antagonist and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug or any combination thereof, as described herein.

A method of treating dry AMD in a subject comprising administering to the subject a therapeutically effective amount of an anti-inflammatory to thereby treat the dry AMD is disclosed. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of one or more anti-inflammatory and a pharmaceutically acceptable carrier, diluent or excipient when used to treat dry AMDand use of the pharmaceutical composition for the manufacture of a medicament for the treatment of dry AMD. The one or more anti-inflammatory may comprise one or more of a COX inhibitor, one or moremineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, one or more glucocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, an antileukotrine and/or a leukotriene receptor antagonist. In one embodiment the anti-inflammatory comprises fludrocortisone.

The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and/or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and/or oxygenation and for treating and preventing peripheral arterial disease.

The invention relates to a drug target for treating cancer and application thereof. The invention relates to application of polypeptide Microcolin H and analogues thereof in preparation of medicines. The medicines comprise medicines for treating neurodegenerative diseases, medicines for treating neurodegenerative diseases, medicines for treating neurodegenerative diseases, medicines for treating neurodegenerative diseases and medicines for treating neurodegenerative diseases. The invention discloses a medicine for treating Duchenne muscular dystrophy. A drug for the treatment of inflammatory diseases; a medicament for treating cardiovascular diseases; the invention discloses a medicine for treating cancers. The invention provides an application of an inhibitor of phosphatidyl alcohol transporter as an anti-tumor drug, and the inhibitor is used as a drug target to develop a therapeutic drug for cancer, cardiovascular diseases and other diseases; the natural polypeptide Microcolin H as well as the analogue and the derivative thereof can accurately target the phosphatidyl alcohol transporter, so that efficient inhibition on tumor cells is realized, the pharmacological action is strong, and the natural polypeptide Microcolin H can be used as the first high-activity and high-selectivity inhibitor of the novel drug target phosphatidyl alcohol transporter, and has a good medicinal prospect.